MedTrace Logo

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

NCT03001609 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-10-03

No results posted yet for this study

Summary

The purpose of this study is to investigate Pharmacokinetics parameters of a single dose \[14C\] AC0010 in male Patients With Advanced NSCLC.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

AC0010

Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]

Sponsors & Collaborators

  • Hangzhou ACEA Pharmaceutical Research Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Feng Shao, Doctor · The First Affiliated Hospital with Nanjing Medical University

  • Yongqian Shu, Doctor · The First Affiliated Hospital with Nanjing Medical University

  • Lihua Bao, Doctor · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-08-31
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001609 on ClinicalTrials.gov